Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-09-25
2004-11-23
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S772500, C514S922000, C514S970000
Reexamination Certificate
active
06821968
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to taurolidine solutions.
DESCRIPTION OF THE BACKGROUND ART
Although taurolidine 1% solutions have been prepared with electrolyte-containing solutions such as ringer solution, there previously has been no suggestion of taurolidine at concentrations greater than 1% in electrolyte solutions such as ringer solution.
Known taurolidine solutions at higher concentrations, e.g., known 2% taurolidine solutions, previously have sometimes had stability problems. For example, droplets clinging on the inside of bottles of 2% taurolidine solution sometimes dry and form crystals, resulting in undesirable particles in the solution. Prior methods for avoiding such problems include storing bottles horizontally on their sides so that droplets do not form in the bottles, and not storing the solutions under refrigeration. However, it is desirable to have bottles of solution which do not require special storage orientation, and which can be refrigerated to extend the shelf-life.
There remains a need in the art for taurolidine solutions having greater stability.
SUMMARY OF THE INVENTION
In accordance with the present invention, a taurolidine composition includes an aqueous solution containing about 1.5-3% by weight taurolidine, the solution containing a stability-enhancing effective amount of at least one physiologically acceptable electrolyte which is present at a concentration sufficient to render said solution substantially isotonic.
REFERENCES:
patent: 4350156 (1982-09-01), Malchesky et al.
patent: 4626536 (1986-12-01), Pfirrmann
patent: 5889183 (1999-03-01), Herdeis et al.
patent: 6080397 (2000-06-01), Pfirrmann
patent: 35 36 560 (1986-04-01), None
patent: 0 139 535 (1985-05-01), None
patent: 0 147 021 (1985-07-01), None
patent: 0 253 662 (1988-01-01), None
patent: 1 040 841 (2000-10-01), None
patent: 1 247 524 (2002-10-01), None
patent: 2 165 752 (1986-04-01), None
Fiedler, Dr. Herbert P., “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und Angrenzende Gebiete”,Editio Canter Aulendorf, pp. 695 (1985).
Janik, Joseph S., et al., “Prevention of Postoperative Peritoneal Adhesions, Efficacy of Povidone”,Arch Surg., vol. 117, pp. 1321-1324, (1982).
Kopple, JD, et al., “Effect of Intravenous Taurine Supplementation on Plasma, Blood Cell, and Urine Taurine Concentrations in Adults Undergoing Long-term Parenteral Nutrition”,Am. J. Clin. Nutr., vol. 52, No. 5., (1990)Abstract.
Stapleton, P. P., et al., “Taurine and Human Nutrition”,Clinical Nutrition, vol. 16, pp. 103-107, (1997).
Wicki et al., “Taurolin—A New Concept in Antimicrobial Chemotherapy in Surgical Infection”,Urban&Scwarzenberg, vol. III, pp. 244-253 (1985).
Kirsch, L., et al., “The Effect of Polyvinylpyrrolidine on the Stability of Taurolidine”,Pharmaceutical Development and Technology, 2:4, 345-356 (1997).
Ed. Geistlich Soehne AG fuer chemische Industrie
Krass Frederick
Rothwell, Figg Ernst & Manbeck, PC
LandOfFree
Stable taurolidine electrolyte solutions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable taurolidine electrolyte solutions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable taurolidine electrolyte solutions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3360953